Evidence map›Paper›PMID 39115297›Full record

ArticleThoracic research and practice2024

Factors Associated with Increasing Costs in Severe Chronic Obstructive Pulmonary Disease Exacerbation: Turkish Thoracic Society Chronic Obstructive Pulmonary Disease Assembly.

Ayşe Baha, Nurdan Köktürk, Caner Baysan, Burcu Öztürk, Sümeyye Kodalak Cengiz, Yelda Varol, Aydan Mertoğlu, Ali Kadri Çırak, Onur Turan, Neşe Dursunoğlu and 8 more

Abstract read
In one paragraph

Article in Thoracic research and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ayşe BahaDepartment of Chest Diseases, Girne American University Faculty of Medicine, Girne, Turkish Republic of Northern Cyprus.
Nurdan KöktürkDepartment of Chest Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey.
Caner BaysanDepartment of Public Health/Epidemiology, İzmir Democracy University Faculty of Medicine, İzmir, Turkey.
Burcu ÖztürkDepartment of Chest Diseases, 25 Aralık State Hospital, Gaziantep, Turkey.
Sümeyye Kodalak CengizDepartment of Chest Diseases, Kartal Lütfi Kırdar Traning and Research Hospital, İstanbul, Turkey.
Yelda VarolDepartment of Chest Diseases, Dr. Suat Seren Chest Diseases and Chest Surgery Traning and Research Hospital, İzmir Health Sciences University, İzmir, Turkey.
Aydan MertoğluDepartment of Chest Diseases, Dr. Suat Seren Chest Diseases and Chest Surgery Traning and Research Hospital, İzmir Health Sciences University, İzmir, Turkey.
Ali Kadri ÇırakDepartment of Chest Diseases, Dr. Suat Seren Chest Diseases and Chest Surgery Traning and Research Hospital, İzmir Health Sciences University, İzmir, Turkey.
Onur TuranDepartment of Chest Diseases, İzmir Katip Çelebi University Faculty of Medicine, İzmir, Turkey.
Neşe DursunoğluDepartment of Chest Diseases, Pamukkale University Faculty of Medicine, Denizli, Turkey.
Nilüfer SavurmuşDepartment of Chest Diseases, Burdur State Hospital, Burdur, Turkey.
Alev GürgünDepartment of Chest Diseases, Ege University Faculty of Medicine, İzmir, Turkey.
Funda ElmasDepartment of Chest Diseases, Ege University Faculty of Medicine, İzmir, Turkey.
Lütfi ÇöplüDepartment of Chest Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Ümran SertçelikDepartment of Chest Diseases, Ankara City Hospital, Ministry of Health University, Ankara, Turkey.
Reyhan YıldızDepartment of Chest Diseases, Süreyyapaşa Chest Diseases and Chest Surgery Traning and Research Hospital, İstanbul, Turkey.
Özmen İpekDepartment of Chest Diseases, Süreyyapaşa Chest Diseases and Chest Surgery Traning and Research Hospital, İstanbul, Turkey.
Aylin Özgen AlpaydınDepartment of Pulmonary Diseases, Dokuz Eylül University School of Medicine, İzmir, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) that is the third leading cause of death in the world is one of the main economic burden. The cost is primarily due to COPD exacerbations and hospitalizations. We aimed to determine the factors associated with increasing costs in severe COPD exacerbation. It was a multicenter and prospective observational recording study. 294 patients who severe COPD exacerbation were included in the study. An amount of more than 429.58 euros was accepted as increasing costs (IC). Factors associated with IC were determined by regression analysis. Mean age was 69.90 ± 9.79/years (minimum: 40 maximum: 95), mean costs were 594.9 ± 70.9 euros. About 83.7% of the patients were male, 24.1% (71) were active smokers, and 81% (238) had at least 1 comorbidity. Factors associated with IC in the regression analysis were delay of discharge (due to prolonged consultation), antibiotic use longer than 7 days, need to enteral/parenteral feeding, application of pulmonary rehabilitation (physiotherapy) at hospitalization, and refusal to be discharged. The increasing costs in severe COPD exacerbation depends not only treatment but also the patient's social status and hospital-related factors. We think that the cost of severe COPD exacerbation can be reduced by interventions on interchangeable factors such as patient's social status and hospital-related factors.

Identifiers

PMID39115297
PMCPMC11158616

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.